PBMs profit off expensive niche meds

Pharmacy benefits managers are building lucrative side businesses in specialty drugs, becoming in some cases the sole distributors for certain niche medications. Critics say distributing these drugs--whose prices are rising much faster than other meds'--could conflict with the PBMs' primary mission of keeping overall drug prices down for health insurers.

- read the story in the New York Times

Suggested Articles

Teva is reportedly going for a moonshot with a $15 billion drug offer to settle its opioid cases. It's a plan that might just work, one analyst said.

CSL has sued a former exec who its says stole thousands of key documents as he left for competitor Pharming.

Influential U.S. cost watchdog ICER gave its blessing to Johnson & Johnson and Amarin's CV drugs. But there's a big catch for both meds.